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714Objective: The establishment of reliable markers to monitor adequate tissue perfusion during extracorporeal life
support is clinically important to improve outcomes.
Methods:We evaluated 115 consecutive adult patients (aged 61.7 13.4 years, 59 female patients) undergoing
extracorporeal life support to manage low cardiac output syndrome after major cardiac surgery. The blood
lactate levels serially measured during extracorporeal life support (at 6, 12, and 24 hours) were analyzed.
Results: Forty-seven patients (40.8%) were weaned off extracorporeal life support successfully, and 32 patients
(27.8%) survived to discharge. On logistic regression analysis, a high blood lactate level before extracorporeal
life support (relative risk [RR], 1.19; 95% confidence interval [CI], 1.06-1.34) and cardiopulmonary bypass
weaning failure after surgery (RR, 4.39; 95% CI, 1.44-13.35) emerged as baseline risk factors of mortality.
After adjustment with these factors, blood lactate levels at 6 hours (RR, 1.24; 95% CI, 1.06-1.46), 12 hours
(RR, 1.35; 95% CI, 1.10-1.67), and 24 hours (RR, 1.46; 95% CI, 1.10-1.93) were predictive of mortality.
When the predictive values of serial blood lactate levels for mortality were assessed using the receiver operating
characteristic method, the greatest accuracy was obtained at cutoff values of 7.05 mmol/L at 6 hours (sensitivity,
75.5%; specificity, 75.0%), 4.95 mmol/L at 12 hours (sensitivity, 70.4%; specificity, 76%), and 4.15 mmol/L
at 24 hours (sensitivity, 62%; specificity, 93.1%).
Conclusions: Blood lactate measurement can be used as a reliable tool for monitoring adequate tissue perfusion
during extracorporeal life support and was strongly predictive of mortality. Therefore, in patients without
adequate decrement in lactate levels during extracorporeal life support, potential factors responsible for
inadequate perfusion should be identified and corrected. (J Thorac Cardiovasc Surg 2014;148:714-20)With the technologic advancement of extracorporeal life
support (ECLS) and improvement in its management
strategies, the use of ECLS has been generalized in clinical
practice over the past decade. ECLS can provide total
circulatory support with fully oxygenated blood so that
systemic tissue perfusion is satisfied in patients with severe
respiratory or circulatory failure. Nevertheless, achieving
adequate tissue perfusion can be disturbed by unexpected
clinical situations, such as device-related problems,
cannulation-related complications, and hemorrhagic
events. These situations may lead to tissue hypoperfusion
and consequent end-organ damage, ultimately hampering
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The Journal of Thoracic and Cardiovascular Surgof suboptimal tissue perfusion despite the ECLS
implementation will be clinically important to identify
correctable factors of hypoperfusion and thereby to
improve the outcomes. Nonetheless, the reliable
monitoring markers of adequate tissue perfusion during
ECLS have not been established to date.
High lactate level is known to be an independent
predictor of low cardiac output syndrome and major
complications after cardiac surgery.3,4 Blood lactate level
can be promptly measured in intensive care unit (ICU)
settings from simple arterial blood gas analysis (ABGA)
samplings. In this study, we hypothesized that arterial
blood lactate level during ECLS can be used as a reliable
predictive marker of mortality. Therefore, we sought to
evaluate the role of serially measured arterial lactate level
during ECLS as a monitoring tool for tissue perfusion in
the setting of post-cardiac surgery ECLS.METHODS
Patients
Between May 2005 and December 2012, 10,197 adult patients
underwent major cardiac surgery at the AsanMedical Center, Seoul, Korea.
These surgeries included valve surgery, coronary artery bypass grafting,
aortic surgery, resection of cardiac tumors, pericardiectomy, pulmonary
thromboembolectomy, and heart transplantation. Of these patients, 125
were supported with venoarterial-type ECLS for low cardiac outputery c August 2014
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Msyndrome after major cardiac surgery at the Asan Medical Center, Seoul,
Korea. After exclusion of 10 patients who underwent preoperative
ECLS, 115 patients were included in this study. Clinical situations that
required postoperative ECLS were as follows: (1) 48 patients with usual
postoperative low cardiac output syndrome that was unresponsive to
inotropics or intra-aortic balloon pumping, (2) 27 patients with witnessed
cardiac arrest that was unresponsive to standard advanced cardiopulmonary
life support, and (3) 40 patients with postoperative cardiopulmonary bypass
(CPB) weaning failure.
The study was approved by the institutional ethics committee/review
board of the University of Ulsan, and the requirement for informed patient
consent was waived in view of the retrospective nature of the study.
Extracorporeal Life Support Devices and
Management
Venoarterial ECLS was implemented at the common femoral artery
and vein or internal jugular vein using the Seldinger technique in all
115 patients. The ECLS system consisted of a centrifugal pump, a hollow
fiber membrane oxygenator with an integral heat exchanger, and a
heparin-bound circuit. Three types of ECLS system were used: the Capiox
Emergent Bypass System (Terumo Corp, Tokyo, Japan) was used for
94 patients (81.7%), the PLS System (Maquet, Hirrlingen, Germany)
was used for 14 patients (12.2%), and the Bio-Console 560 System
(Medtronic, Inc, Minneapolis, Minn) was used for 7 patients (6.1%).
Blood lactate level measurement was performed routinely every 2 to 3
hours from simple ABGA samples. The ABGA samples were analyzed by
GEM Premier 3000 (Instrumentation Laboratory, Lexington, Mass).
An intravenous heparin bolus of 100U/kg was administered to achieve a
celite activated clotting time (measured using a Hemochron 401 machine,
Soma Technology, Bloomfield, Conn) of 300 seconds before cannulation of
arterial and venous catheter. After the initiation of ECLS, the activated
clotting time was maintained within a range of 180 to 200 seconds. From
2010, nafamostat mesilate (Futhan; Torii Pharmaceutical, Tokyo, Japan),
a synthetic serine protease inhibitor, was adopted to use as an alternative
anticoagulant to heparin for patients with a high risk of bleeding. For these
patients, a half-dose of heparin was administered before cannulation, and
activated clotting time was maintained within 160 to 180 seconds after
the administration of a starting dose of 0.75 mg/kg nafamostat mesilate.
The patients (n ¼ 5) with severe coagulopathy in the immediate
postoperative period were not administered heparin or nafamostat mesilate
until the bleedingwas controlled. The details of coagulation strategy during
ECLS and ECLS weaning protocol have been described.5
We tried to maintain the ECLS blood flow greater than the cardiac index
of 2.4 L/min/m2. Tomaintain the mean arterial pressure of 60 to 70mmHg,
vasopressors such as norepinephrine or vasopressin were administered as
needed. Red blood cells and platelets were transfused to maintain
the hematocrit of 30% to 35% and platelet count greater than
100 3 103/mm3 for patients with a high bleeding risk. An antegrade
perfusion catheter for distal limb perfusion was routinely placed distal to
the arterial cannulation site, except in the case of the failure to implant
the catheter because of technical difficulties.The Journal of Thoracic and CaStatistical Analysis
Categoric variables are presented as frequencies and percentages, and
were compared using the Chi-square test or Fisher exact test. Continuous
variables are expressed as mean  standard deviation and were compared
using the Student unpaired t test. To determine the baseline risk factors for
mortality, logistic regression models were used. At the first stage of the
analyses, baseline characteristics of patients and variables related to
ECLS were considered in the logistic regression model. Variables with a
P value of .20 or less in univariable analyses were candidates for the
multivariable models. Multivariable analyses involved a backward
elimination technique, and only variables with a P value of .10 or less
were used in the final model. To evaluate the impact of post-ECLS lactate
level on death, further multivariable analyses were conducted that involved
serial post-ECLS lactate levels at each point and significant variables
affecting mortality in the second stage of the analyses. Results were
expressed as a relative risk (RR) with 95% confidence intervals (CIs).
The predictive value of post-ECLS lactate level for mortality was evaluated
by analyzing areas under receiver operating characteristic (ROC) curves,
with their 95% CI. The optimal cutoff value corresponded to the value
with the greatest accuracy. Survival was estimated by the Kaplan–Meier
method and compared by the log-rank test. All reported P values are
2-sided. Statistical analyses were performed with SPSS 18.0 for Windows
Software (IBM, Armonk, NY).RESULTS
The baseline characteristics and clinical data related to
ECLS of the patients are shown in Tables 1 and 2,
respectively. The patients who died in-hospital required a
longer CPB time during surgery and were more likely to
undergo ECLS at the end of the operation because of
CPB weaning failure than those who survived to discharge,
whereas there were no significant differences between the 2
groups in other baseline profiles. The levels of arterial blood
lactate before and after the initiation of ECLS were signif-
icantly higher in patients who died in-hospital compared
with those in the group of survivors to discharge.
Sixty-three patients (54.8%) experienced at least 1
complication during ECLS. Table 3 provides the details of
complications that occurred during ECLS. The serial blood
lactate levels at 6 hours (9.73  4.48 vs 7.01  4.39;
P ¼ .007), 12 hours (8.10  4.76 vs 5.14  3.74;
P ¼ .003), and 24 hours (6.48  4.98 vs 4.00  2.92;
P ¼ .008) after ECLS initiation were significantly higher
in the patients who had at least 1 complication (n ¼ 63)
than the patients without complications (n ¼ 52). The
incidence rates of overall complications were significantly
higher in patients who died in-hospital than those who
survived to discharge (P ¼ .003).
The overall outcomes of ECLS are summarized
in Figure 1. Two patients underwent successful heart
transplantation and survived to discharge. Forty-seven
patients (40.8%) were weaned off ECLS successfully;
however, 17 patients died after successful weaning from
ECLS in-hospital. The cause of death after successful
weaning was multiple organ failure in 6 patients,
profound cardiac failure in 3 patients, sepsis in 2 patients,
pan-peritonitis in 2 patients, aortic rupture in 2 patients,rdiovascular Surgery c Volume 148, Number 2 715
TABLE 1. Baseline characteristics of patients who underwent extracorporeal life support after major cardiac surgery
Variables Total (n ¼ 115) Discharged (n ¼ 32) Died in-hospital (n ¼ 83) P value
Age, y 61.7  13.4 58.2  16.1 63.0  11.9 .088
Male gender, n (%) 56 (48.7) 16 (50) 40 (48.2) .83
Body surface area, m2 1.65  0.19 1.60  0.18 1.66  0.20 .24
Hypertension, n (%) 53 (46.1) 12 (37.5) 41 (49.4) .40
Diabetes mellitus, n (%) 23 (20) 6 (18.8) 17 (20.5) >.99
Echocardiographic data
LV end-systolic dimension, mm 36.4  11.5 38.5  14.5 35.5  10.2 .26
LV end-diastolic dimension, mm 53.1  9.6 54.2  11.6 52.7  8.8 .48
LV ejection fraction,% 57.1  14.3 51.7  16.7 55.0  13.3 .22
LV mass, g 192.4  73.8 186.4  67.3 194.8  76.4 .54
Operation type .49
Valve surgery, n (%) 31 (30.0) 10 (31.3) 21 (25.3)
CABG, n (%) 25 (21.7) 8 (25) 17 (20.5)
Valve þ CABG, n (%) 15 (13.0) 2 (6.3) 13 (15.7)
Aorta surgery, n (%) 9 (7.8) 2 (6.3) 7 (8.4)
Aorta þ valve or CABG, n (%) 18 (15.7) 3 (9.4) 15 (18.1)
Others, n (%) 17 (14.8) 7 (21.9) 10 (12.0)
Previous cardiac surgery, n (%) 14 (12.2) 2 (6.3) 12 (14.5) .34
ACC time, min 104.7  83.5 109.5  76.3 102.9  86.6 .98
CPB time, min 232.4  134.0 190.0  85.9 248.6  146.1 .014
Values are n (%) or mean  SD. ACC, Aortic crossclamp; CABG, coronary arterial bypass grafting; CPB, cardiopulmonary bypass; LV, left ventricular.
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Mintracerebral hemorrhage in 1 patient, and gastrointestinal
bleeding in 1 patient. Consequently, including 2 heart
transplantation recipients, 32 patients (27.8%) survived to
discharge.
On logistic regression analysis, a high blood lactate
level before ECLS (RR, 1.19; 95% CI, 1.06-1.34) and
CPB weaning failure after surgery (RR, 4.39; 95% CI,
1.44-13.35) emerged as significant and independent
baseline risk factors of mortality (Table 4).
After adjustment with these baseline risk factors, high
blood lactate levels at 6 hours (RR, 1.24; 95% CI, 1.06-
1.46), 12 hours (RR, 1.35; 95%CI, 1.10-1.67), and 24 hours
(RR, 1.46; 95% CI, 1.10-1.93) after the initiation of ECLS
were significantly predictive of mortality (Table 4).
The predictive values of serial blood lactate levels after
the initiation of ECLS for mortality were assessed usingTABLE 2. Extracorporeal life support data
Variables Total (n ¼ 115) D
Clinical situation of ECLS implantation
At the end of operation, n (%) 41 (35.7)
Arrest, n (%) 27 (23.5)
Interval from operation finish to ECLS, h 13.5 (0.6-701.9)
Blood lactate level, mmol/L
Before initiating ECLS 9.07  4.59
6 h after ECLS initiation 8.47  4.61
12 h after ECLS initiation 6.73  4.54
24 h after ECLS initiation 5.27  4.27
Duration of ECLS, h 71.3 (0.5-712.9)
Use of nafamostat anticoagulant, n (%) 26 (22.6)
Values are n (%) mean  standard deviation or median (range). ECLS, Extracorporeal lif
716 The Journal of Thoracic and Cardiovascular Surgthe ROC method. The greatest accuracy for prediction of
mortality was obtained at cutoff values of 7.05 mmol/L at
6 hours (sensitivity, 75.5%; specificity, 75.0%), 4.95
mmol/L at 12 hours (sensitivity, 70.4%; specificity,
76%), and 4.15 mmol/L at 24 hours (sensitivity, 62%;
specificity, 93.1%), showing an area under curve of 0.76
at 6 hours, 0.79 at 12 hours, and 0.76 at 24 hours after the
initiation of ECLS (Figure 2).
Complications tended to occur less frequently in patients
whose lactate level was below the cutoff value than those
whose lactate level was greater than the cutoff value at
each point (Figure 3).
The differences in survival according to the arterial blood
lactate levels after the initiation of ECLS are illustrated in
Figure 4. Survivals were higher in the patients whose
arterial blood lactate level was below the cutoff valuesischarged (n ¼ 32) Died in-hospital (n ¼ 83) P value
6 (18.8) 35 (42.2) .029
7 (21.9) 20 (24.1) .80
11.3 (0.8-50.8) 14.1 (0.6-701.9) .051
7.33  3.90 9.78  4.67 .002
5.81  3.47 9.92  4.54 <.001
3.77  2.19 8.16  4.70 <.001
2.87  1.28 6.71  4.77 <.001
70 (0.8-460) 71.9 (0.5-712.9) .29
11 (34.4) 15 (18.1) .12
e support.
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TABLE 3. Early outcomes of patients who underwent extracorporeal
life support
Total (n ¼ 115)
In-hospital death, n (%) 83 (72.2)
Successful weaning, n (%) 47 (40.8)
No. of patients with complications during ECLS
Mediastinal bleeding, n (%) 42 (36.5)
Reoperation for bleeding 31 (27.0)
Massive bleeding (not operated) 11 (9.6)
Lower limb ischemia, n (%) 19 (16.5)
Bowel ischemia, n (%) 8 (7.0)
Cannulation-related complications, n (%) 13 (11.3)
Values are n (%). ECLS, Extracorporeal life support.
Park et al Perioperative Managementthan in the patients whose lactate level was greater than
cutoff values at each point.DISCUSSION
Although the establishment of reliable markers to
monitor adequate tissue perfusion during ECLS is clinically
important to improve outcomes, clinical studies regarding
monitoring tools during ECLS have been rare to date.
Because reduced arterial pulse pressure is known to be
indicative of decreased left ventricular systolic function,6FIGURE 1. Flowchart of the outcomes in patients rec
The Journal of Thoracic and Caa recent study suggested arterial pulse pressure as a
prognostic marker for mortality in patients receiving
ECLS.7 However, arterial pulse pressure neither reflects
the degree of tissue perfusion nor has an indeterminate
nature; therefore, its use as a reliable monitoring tool during
ECLS is doubtful.
Mixed venous oxygen saturation, a commonly used
monitoring parameter in ICU, measured from the
pulmonary artery, represents the balance between oxygen
delivery and consumption.8 A significant proportion of
patients receiving ECLS are typically seriously collapsed
in hemodynamics at the time of ECLS. Consequently,
peripheral arteriovenous shunt and blockade of oxygen
delivery frequently appear in those patients. In this
situation, mixed venous oxygen saturation is known to be
unreliable and inadequate to monitor tissue perfusion.
Furthermore, early detection and identification of end-
organ injury, and consequences of the tissue hypoxia, are
not available.
Pyruvate, intermediate metabolite of glycolysis, is
converted to lactate by lactate dehydrogenase in anaerobic
condition. The normal plasma lactate level is generally
kept at 0.3 to 1.3 mmol/L, which represents a balance
between lactate production and removal. However, tissueeiving ECLS. ECLS, Extracorporeal life support.
rdiovascular Surgery c Volume 148, Number 2 717
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TABLE 4. Multivariable risk factors analyses for in-hospital
mortality and impact of lactate level on mortality
Variables RR 95% CI P value
Pre-ECLS baseline variables
Arterial lactate level before ECLS 1.19 1.06-1.34 .003
CPB weaning failure after surgery 4.39 1.44-13.35 .009
Arterial lactate levels during ECLS*
6 h after ECLS initiation 1.24 1.06-1.46 .009
12 h after ECLS initiation 1.35 1.10-1.67 .005
24 h after ECLS initiation 1.46 1.10-1.93 .008
CI, Confidence interval; CPB, cardiopulmonary bypass; ECLS, extracorporeal life
support; RR, relative risk. *Adjusted by ‘‘arterial lactate level before ECLS’’ and
‘‘CPB weaning failure.’’
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Mhypoxia forces anaerobic metabolism of glucose, which
leads to enhanced production of lactate than its removal,
resulting in hyperlactatemia. Several studies have shown
intimate associations of elevated lactate level with worse
outcomes in major cardiac surgery.9,10 Increased lactate
release during reperfusion after cardioplegic arrest in
cardiac surgical patients is known to be an independent
predictor of low cardiac output syndrome.3 A recent study
by Hajjar and colleagues4 demonstrated that the lactate
level 6 hours after ICU admission is an independent
predictor for major complications after cardiac surgery,
and they suggested that a strategy of aiming to lower serum
lactate level using other hemodynamic parameters mayFIGURE 2. ROC curves for the predictive value of arterial lactate level for mo
ECLS. AUC, Area under the curve; CI, confidence interval.
718 The Journal of Thoracic and Cardiovascular Surgreduce the incidence of major complications after cardiac
surgery. Furthermore, a prospective, randomized study
demonstrated that normalization of lactate level as a
therapeutic goal can shorten the length of hospital day
and decrease the morbidity.11
Consistent with the cited reports, our previous study
showed a close association between high blood lactate level
and mortality in patients who underwent ECLS after major
cardiac surgery.5 High lactate level before ECLS initiation
was an independent predictor of mortality, and the lactate
level of 7.9 mmol/L before initiation of ECLS, assessed
using the ROC method, was the most accurate predictive
value for mortality. This result is supported by other
studies.12,13
ECLS can provide total circulatory support with fully
oxygenated blood so that oxygen delivery and systemic
tissue perfusion are satisfied in patients with severe
respiratory or circulatory failure. Consequent rapid
decrement of lactate level is expected in these patients.
Nevertheless, a significant number of patients who
underwent ECLS do not seem to show a remarkable
decrement in blood lactate level. We hypothesized that the
patients who do not show an appropriate decrement in blood
lactate level after the initiation of ECLS may have
inadequate tissue perfusion related to complications or
insufficient support. The present study demonstrated that
serially measured arterial blood lactate levels at 6 hours,rtality at 6 hours (A), 12 hours (B), and 24 hours (C) after the initiation of
ery c August 2014
FIGURE 3. The incidence rate of the overall complications according to
the cutoff arterial lactate levels at 6 hours, 12 hours, and 24 hours after the
initiation of ECLS. ECLS, Extracorporeal life support.
Park et al Perioperative Management12 hours, and 24 hours after ECLS initiation were
independent predictors of mortality even after adjustment
with pre-ECLS risk factors. The cutoff values of predictiveFIGURE 4. Kaplan–Meier analysis revealing differences in mortality accord
(C) after the initiation of ECLS. Lac, Lactate.
The Journal of Thoracic and Cafor mortality gradually declined in serially measured lactate
level after ECLS initiation (Figure 2). These findings
suggest that the failure to achieve adequate decrement in
arterial lactate level shortly after ECLS initiation is
associated with increased mortality in patients with
hyperlactatemia. Therefore, in patients without an adequate
decrement in lactate levels during ECLS, potential factors
responsible for inadequate perfusion should be identified
and corrected. In these regards, this study proposes arterial
lactate measurement as a monitoring tool during ECLS for
the acquisition of satisfactory tissue perfusion. Although
previous studies also have demonstrated an association
between the high blood lactate level after initiation of
ECLS and mortality or weaning failure,14-16 the cited
studies have not shown the predictive role of lactate
measurement as a monitoring tool during ECLS.
Chen and colleagues15 showed a significant correlation
between survival and lactate levels on the first, third,
and seventh days of ECLS. Another recent study also
demonstrated that patients who survived to discharge
showed significantly lower levels of lactate at 48 and
72 hours than nonsurvivors.14 Compared with these earlier
studies, the present study evaluated the influences of blooding to the arterial lactate level at 6 hours (A), 12 hours (B), and 24 hours
rdiovascular Surgery c Volume 148, Number 2 719
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Mlactate levels focusing more on the very early period
(within 24 hours). This is because the postoperative courses
of patients who underwent major cardiac surgery are
dynamic, especially in those who require ECLS, in that
patients’ outcomes are likely to be determined in the very
early postoperative period. For instance, of 83 patients
who died in-hospital in the present study, 23 (27.7%)
died within 3 days of ECLS support and 47 (56.6%) died
within 7 days. These findings indicate that referencing the
lactate levels at 3 or 7 days is too late for many patients;
therefore, we need to establish more reasonable monitoring
methods for very early settings. This is why we focused on
the relatively earlier period of the course compared with
other previous studies.
New techniques, such as laser-Doppler flowmetry,
near-infrared spectroscopy, and sidestream dark-field
imaging, have been introduced to evaluate tissue perfusion
and microcirculation at the bedside.17-19 Although these
techniques might be used as a tailored therapy in the
foreseeable future, practical application of these
equipment and techniques during ECLS in a routine way
may not be feasible because of the associated costs.
Study Limitations
This study is subject to the limitations inherent in
retrospective studies of observational data from a single
center. The study failed to elucidate the direct relation
between the elevated lactate level after the initiation of
ECLS and each complication during ECLS, such as
hemorrhage, bowel ischemia, cannulation-related, and
device-related complications. This may account for the
relatively small number of patients who experienced each
complication.
Lactate level–guided intervention during ECLS is an
important issue according to the study results. However,
the present study could not evaluate whether lactate
level–guided intervention decreased mortality. To address
this issue, ‘‘intention-to-treat’’ basis analyses should be
performed, which is only possible through studies with
prospective designs.
CONCLUSIONS
Establishment of reliable markers to monitor adequate
tissue perfusion during ECLS is clinically important to
improve outcomes. Arterial lactate level after the initiation
of ECLS is strongly predictive of mortality and has the
tendency to decrease sequentially in patients acquiring
satisfactory tissue perfusion. Therefore, arterial lactate
measurement can be used as a valuable and reliable tool
for monitoring adequate tissue perfusion during ECLS.
In patients without adequate decrement in lactate levels
during ECLS, potential factors responsible for inadequate720 The Journal of Thoracic and Cardiovascular Surgperfusion should be identified and corrected. Prospective,
randomized studies targeting normalization of the lactate
level as a therapeutic goal are required to verify the impact
of post-ECLS arterial lactate measurement on the outcomes
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